{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:25:12Z","timestamp":1794435912039,"version":"4.9.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.semnuclmed.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:18:04Z","timestamp":1781065084000},"page":"975-1011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies"],"prefix":"10.1053","volume":"56","author":[{"given":"Parya","family":"Valizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-7905","authenticated-orcid":false,"given":"Payam","family":"Jannatdoust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnoosh","family":"Shahgholianghahfarokhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Menda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Shariftabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2026.05.004_bib0001","unstructured":"Cancer Facts & Figures 2026 | American Cancer Society. Accessed February 8, 2026. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2026-cancer-facts-figures.html"},{"key":"10.1053\/j.semnuclmed.2026.05.004_bib0002","series-title":"Key Statistics for Prostate Cancer | Prostate Cancer Facts","year":"2026"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.004_bib0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/UPJ.0000000000000363","article-title":"The cost of metastatic prostate cancer in the United States","volume":"10","author":"Olsen","year":"2023","journal-title":"Urol Pract"},{"key":"10.1053\/j.semnuclmed.2026.05.004_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2022.05.007","article-title":"Molecular mechanisms underlying the development of neuroendocrine prostate cancer","volume":"86","author":"Liu","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.004_bib0006","article-title":"Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines","volume":"6","author":"Clermont","year":"2019","journal-title":"Int J Endocr Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.004_bib0007","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/pros.24664","article-title":"Diagnosis and management of neuroendocrine prostate cancer","volume":"84","author":"de Kouchkovsky","year":"2024","journal-title":"Prostate"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.05.004_bib0008","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.004_bib0009","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.05.004_bib0010","first-page":"2564","article-title":"High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers1","volume":"85","author":"Halmos","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.004_bib0011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bju.15621","article-title":"The triple-tracer strategy against metastatic prostate cancer (3TMPO) study protocol","volume":"130","author":"Pouliot","year":"2022","journal-title":"BJU Int"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.004_bib0012","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.2967\/jnumed.124.268020","article-title":"Intrapatient intermetastatic heterogeneity determined by triple-tracer PET imaging in mCRPC patients and correlation to survival: the 3TMPO cohort study","volume":"65","author":"Pouliot","year":"2024","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.004_bib0013","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.05.004_bib0014","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/RLU.0000000000002824","article-title":"177Lu-PSMA and 177Lu-DOTATATE therapy in a patient with metastatic castration-resistant prostate cancer and neuroendocrine differentiation","volume":"44","author":"Assadi","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.004_bib0015","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/RLU.0000000000002780","article-title":"Excellent response to 177Lu-DOTATATE peptide receptor radionuclide therapy in a patient with progressive metastatic castration-resistant prostate cancer with neuroendocrine differentiation after 177Lu-PSMA therapy","volume":"44","author":"Liu","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.05.004_bib0016","doi-asserted-by":"crossref","first-page":"E371","DOI":"10.1097\/RLU.0000000000004735","article-title":"177Lu-DOTATATE therapy in a case of castrate-resistant prostate cancer with neuroendocrine differentiation","volume":"48","author":"Shu","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.05.004_bib0017","article-title":"Somatostatin receptor scintigraphy for neuroendocrine pattern in patients with hormonerefractory prostate cancer: preliminary experience","volume":"18","author":"Manassero","year":"2006","journal-title":"Eur Urol Suppl"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.004_bib0018","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clgc.2011.12.004","article-title":"Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt","volume":"10","author":"Matei","year":"2012","journal-title":"Clin Genitourin Cancer"},{"issue":"3B","key":"10.1053\/j.semnuclmed.2026.05.004_bib0019","first-page":"2233","article-title":"Effect of chemotherapy on somatostatin receptor detection with octreotide scintigraphy in hormone-refractory prostate cancer patients","volume":"26","author":"Mencoboni","year":"2006","journal-title":"Anticancer Res"},{"issue":"0","key":"10.1053\/j.semnuclmed.2026.05.004_bib0020","first-page":"696","article-title":"Initial experience with somatostatin receptor (SSTR) imaging and peptide receptor radionuclide therapy for patients with neuroendocrine differentiation (NED) of prostate cancer","volume":"47","author":"Assadi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.004_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RLU.0000000000001424","article-title":"PET\/CT with 68Ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate cancer","volume":"42","author":"Gofrit","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.05.004_bib0022","article-title":"Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET\/CT: preliminary report of in six patients","volume":"3","author":"Savelli","year":"2015","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.004_bib0023","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.21873\/anticanres.15699","article-title":"Treatment outcomes in neuroendocrine prostate cancer","volume":"42","author":"Iwamoto","year":"2022","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.004_bib0024","article-title":"Multitarget molecular imaging in metastatic castration resistant adenocarcinoma prostate cancer with therapy induced neuroendocrine differentiation","volume":"12","author":"Ahumada","year":"2022","journal-title":"Diagnostics"},{"key":"10.1053\/j.semnuclmed.2026.05.004_bib0025","doi-asserted-by":"crossref","DOI":"10.14740\/wjon739w","article-title":"Neuroendocrine differentiation of prostate cancer metastases evidenced \u201cin Vivo\u201d by 68Ga-DOTANOC PET\/CT: two cases","author":"Savelli","year":"2014","journal-title":"World J Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.004_bib0026","article-title":"Ectopic adrenocorticotrophic hormone syndrome secondary to treatment-related neuroendocrine differentiation of metastatic castrate-resistant prostate cancer","volume":"2023","author":"Tan","year":"2023","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.05.004_bib0027","doi-asserted-by":"crossref","first-page":"E480","DOI":"10.1097\/RLU.0000000000003685","article-title":"Prostate cancer with neuroendocrine differentiation recurring after treatment with 177Lu-PSMA: a chance for 177Lu-DOTATATE therapy?","volume":"46","author":"Nesari Javan","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.05.004_bib0028","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/RLU.0000000000001419","article-title":"68Ga-DOTATOC and 68Ga-PSMA PET\/CT unmasked a case of prostate cancer with neuroendocrine differentiation","volume":"41","author":"Chen","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.05.004_bib0029","doi-asserted-by":"crossref","unstructured":"Hope T.A, Aggarwal R., Simko J.P, Henry \u00a7||, Vanbrocklin F., Ryan C.J. Somatostatin imaging of neuroendocrine-differentiated prostate cancer. 2015. www.nuclearmed.com","DOI":"10.1097\/RLU.0000000000000776"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.004_bib0030","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00259-024-06905-5","article-title":"Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer","volume":"52","author":"Santo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.004_bib0031","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/j.clgc.2021.01.008","article-title":"Molecular imaging of neuroendocrine differentiation of prostate cancer: a case series","volume":"19","author":"Iravani","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.004_bib0032","article-title":"De novo purely prostatic large-cell neuroendocrine carcinoma with thyroid and adrenal metastases","volume":"2022","author":"Karvounis","year":"2022","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1053\/j.semnuclmed.2026.05.004_bib0033","article-title":"Neuroendocrine prostate cancer treated with multimodal examination and therapy: a case report","volume":"44","author":"Hara","year":"2022","journal-title":"Urol Case Rep"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.004_bib0034","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000511070","article-title":"Pelvic MRI, FDG-PET\/CT, and somatostatin receptor scintigraphy findings of treatment-related neuroendocrine-differentiated prostate cancer","volume":"14","author":"Kitajima","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.004_bib0035","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3892\/mco.2015.645","article-title":"Neuroendocrine differentiation in castration-resistant prostate cancer: a case report","volume":"3","author":"Priftakis","year":"2015","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.004_bib0036","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2009.01.019","article-title":"Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate","volume":"56","author":"Molenaar","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.004_bib0037","doi-asserted-by":"crossref","first-page":"266","DOI":"10.33160\/yam.2024.08.010","article-title":"Excellent response to 177Lu-DOTATATE peptide receptor radionuclide therapy in a patient with treatment-related neuroendocrine prostate cancer with urinary retention and rectal obstruction: a case report","volume":"67","author":"Yasukawa","year":"2024","journal-title":"Yonago Acta Med"},{"key":"10.1053\/j.semnuclmed.2026.05.004_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1289272","article-title":"Case report: 177Lu DOTA-TATE: a new scheme for the treatment of prostate neuroendocrine cancer","volume":"13","author":"Yu","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.004_bib0039","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/RLU.0000000000005131","article-title":"Dual 177Lu\u2013prostate-specific membrane antigen and 177Lu-DOTATATE therapy in metastatic castration-resistant prostate cancer with neuroendocrine differentiation","volume":"49","author":"Beyhan","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.004_bib0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13139-023-00800-x","article-title":"Molecular imaging in recurrent prostate cancer presented as a mixed small neuroendocrine tumor\/acinar adenocarcinoma","volume":"57","author":"Al-Ibraheem","year":"2023","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.004_bib0041","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/RLU.0000000000002013","article-title":"Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET\/CT and 68Ga-DOTANOC PET\/CT over 68Ga-PSMA PET\/CT","volume":"43","author":"Parida","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"5-6","key":"10.1053\/j.semnuclmed.2026.05.004_bib0042","first-page":"224","article-title":"Metastatic prostate adenocarcinoma with neuroendocrine differentiation on 18F-FDG PET\/CT, 68Ga-PSMA PET\/CT and 68Ga-DOTA TATE PET\/CT with injected ultra-low-activity","volume":"46","author":"Zhang","year":"2022","journal-title":"Med Nucl"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.004_bib0043","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2967\/jnumed.119.231068","article-title":"Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: A mechanistic perspective for 18 F-FDG imaging of PSMA-suppressed tumors","volume":"61","author":"Bakht","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.004_bib0044","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-020-00723-0","article-title":"[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study","volume":"10","author":"Hober\u00fcck","year":"2020","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.004_bib0045","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.clgc.2016.09.002","article-title":"Correlation of PSMA-targeted 18F-DCFPyL PET\/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate cancer","volume":"15","author":"Tosoian","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.004_bib0046","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1159\/000540573","article-title":"A complete response to combined immunotherapy in a patient with an ATM plus SF3B1 mutation and a moderate tumor mutational burden with a high-grade treatment-emergent neuroendocrine prostate cancer: case report and review of the literature","volume":"17","author":"Ferreira Bruzzi Porto","year":"2024","journal-title":"Case Rep Oncol"},{"key":"10.1053\/j.semnuclmed.2026.05.004_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1398673","article-title":"Systemic metastases in large cell neuroendocrine prostate cancer: a rare case report and literature review","volume":"14","author":"Xiao","year":"2024","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2026.05.004_bib0048","doi-asserted-by":"crossref","unstructured":"Spieth M.E, Lin Y.G, Nguyen T.T. Diagnosing and treating small-cell carcinomas of prostatic origin. Vol 27. 2002.","DOI":"10.1097\/00003072-200201000-00003"},{"key":"10.1053\/j.semnuclmed.2026.05.004_bib0049","article-title":"A rare case of neuroendocrine prostate cancer detected on 68Ga \u2013 DOTANOC positron emission tomography\/computed tomography (PET\/CT)","author":"Kumar","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.004_bib0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/ijnm.IJNM_127_20","article-title":"Obstructive jaundice: An unusual presentation of neuroendocrine differentiation in prostatic adenocarcinoma","volume":"36","author":"Santhosh","year":"2021","journal-title":"Indian J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.004_bib0051","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/RLU.0000000000001618","article-title":"Molecular imaging in neuroendocrine differentiation of prostate cancer","volume":"42","author":"Usmani","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"21","key":"10.1053\/j.semnuclmed.2026.05.004_bib0052","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.2169\/internalmedicine.0630-17","article-title":"Imaging somatostatin receptor activity in neuroendocrine-differentiated prostate cancer","volume":"57","author":"Mori","year":"2018","journal-title":"Internal Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.004_bib0053","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1055\/s-0037-1621112","article-title":"Ga-DOTATOC-PET\/CT detects neuroendocrine differentiation of prostate cancer metastases","volume":"48","author":"Souvatzoglou","year":"2009","journal-title":"Nuklearmedizin"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.004_bib0054","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/ijnm.ijnm_193_22","article-title":"Primary neuroendocrine tumor of prostate in a case of metastatic adenocarcinoma of lung: rare entity with histopathological and gallium 68 DOTANOC positron emission tomography correlation","volume":"38","author":"Dev","year":"2023","journal-title":"Indian J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.004_bib0055","doi-asserted-by":"crossref","first-page":"449","DOI":"10.21037\/jgo.2016.01.06","article-title":"Ga-68 DOTANOC PET\/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India","volume":"7","author":"Pruthi","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.004_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11030468","article-title":"Neuroendocrine differentiation of prostate cancer is not systematically associated with increased 18f-fdg uptake","volume":"11","author":"Bauckneht","year":"2021","journal-title":"Diagnostics"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.05.004_bib0057","doi-asserted-by":"crossref","first-page":"E428","DOI":"10.1097\/RLU.0000000000003721","article-title":"68Ga-DOTATATE PET\/CT uptake in prostate with an incidental finding of prostatic acinar adenocarcinoma and metastatic neuroendocrine cancer to the liver","volume":"46","author":"Nisar","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"03","key":"10.1053\/j.semnuclmed.2026.05.004_bib0058","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4103\/wjnm.WJNM_11_19","article-title":"Neuroendocrine prostate cancer or prostatitis? An unusual false positive on gallium-68 DOTA-Tyr3-octreotate positron emission tomography\/computed tomography in a patient with known metastatic neuroendocrine tumor","volume":"18","author":"Schmidt","year":"2019","journal-title":"World J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.004_bib0059","first-page":"108","article-title":"Gallium-68 DOTATOC PET\/CT in vivo characterization of somatostatin receptor expression in the prostate","volume":"29","author":"Todorovi\u0107-Tirnani\u0107","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.004_bib0060","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"24","key":"10.1053\/j.semnuclmed.2026.05.004_bib0061","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246039","article-title":"Prognostic evaluation of metastatic castration resistant prostate cancer and neuroendocrine prostate cancer with [68Ga]Ga DOTATATE PET-CT","volume":"14","author":"Bilen","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.05.004_bib0062","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.biopha.2008.01.010","article-title":"Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET","volume":"62","author":"Fanti","year":"2008","journal-title":"Biomed Pharmacother"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129982600111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129982600111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:27:12Z","timestamp":1794432432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000129982600111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S000129982600111X"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.05.004","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}